ULTRAGENYX
NASDAQ: RARE (Ultragenyx Pharmaceutical Inc.)
Kemas kini terakhir: 8 jam lalu14.30
-0.10 (-0.69%)
| Penutupan Terdahulu | 14.40 |
| Jumlah Dagangan | 3,251,763 |
| Harga / Jualan (P/S) | 2.01 |
| Harga / Buku (P/B) | 19.68 |
| Julat 52 Minggu |
| Margin Keuntungan | -93.04% |
| Margin Operasi (TTM) | -102.62% |
| EPS Cair (TTM) | -5.83 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 588.24% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | -389.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -172.94 M |
| Pulangan Atas Aset (ROA TTM) | -24.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -377.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ultragenyx Pharmaceutical Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.38 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.20% |
| % Dimiliki oleh Institusi | 99.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sands Capital Management, Llc | 30 Jun 2026 | 3,158,368 |
| Bellevue Group Ag | 30 Jun 2026 | 1,982,775 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,717,505 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HUIZENGA THEODORE ALAN | - | 14.85 | -161 | -2,391 |
| Jumlah Keseluruhan Kuantiti Bersih | -161 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,391 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 14.85 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HUIZENGA THEODORE ALAN | Pegawai | 03 Sep 2026 | Jual (-) | 161 | 14.85 | 2,391 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |